The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mpn content recommended for you
Prithviraj BoseDuring the Texas MPN Workshop (TMW) 2022, the MPN Hub was pleased to speak to Prithviraj Bose, MD Anderson Cancer Center, Houston, US. We asked about understanding and managing cytopenic myelofibrosis (MF).
How to understand and manage cytopenic myelofibrosis?
Bose begins by identifying anemia and thrombocytopenia as the primary cytopenias in MF, posing challenges in the management of patients with MF. Bose notes that there are no drugs approved specifically for the improvement of cytopenias in MF and then discusses two ways to manage cytopenias.
The first approach is using agents that specifically improve cytopenias, such as luspatercept, which is being developed in phase III settings to improve anemia in patients who are on ruxolitinib and still require blood transfusion. The second approach is to use agents with multiple targets, namely cytopenias and disease-related symptoms. Pelabresib, momelotinib, pacritinib, and implications of the clinical trials investigating these agents are discussed. Bose finishes with the optimal dosing of ruxolitinib in patients with cytopenic MF.
Your opinion matters
On average, how many patients with myelofibrosis do you see in a month?